Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dye-Enhanced ultrasound may improve liver biopsy success

NCT ID NCT07249268

Diagnosis Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two ways to guide a needle biopsy of suspicious liver lumps: standard ultrasound and contrast-enhanced ultrasound (CEUS), which uses a special dye to make blood vessels and lesions show up better. Researchers looked at 330 patients to see if CEUS leads to more successful biopsies. The goal is to find out if the dye helps doctors get a better tissue sample for diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
contrast agent (dye) used during ultrasound
What this could lead to
If CEUS proves more effective, it could become the preferred method for guiding liver biopsies, leading to more accurate diagnoses.
What could go wrong
This is a completed study, so results are already known. The benefit may be small or limited to certain types of liver lesions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

330 people

The number who actually took part.

Started

Jan 2022

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients underwent CEUS-guided or conventional US-guided coaxial biopsy for focal hepatic lesions.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Indeterminate liver lesions on prior imaging (CT/MRI). * Coaxial biopsy performed with 18G introducer needle. Exclusion Criteria: * Coagulopathy (INR \>1.5, platelets \<50×109/L). * Contraindications to ultrasound contrast agents.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic lesions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic lesions

Contacts and locations

Locations

  • Department of Ultrasound, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, China

    Xiamen, Fujian, 361000, China